Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.31
ARNA's Cash to Debt is ranked higher than
61% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. ARNA: 2.31 )
ARNA' s 10-Year Cash to Debt Range
Min: 0.64   Max: No Debt
Current: 2.31

Equity to Asset 0.17
ARNA's Equity to Asset is ranked higher than
52% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ARNA: 0.17 )
ARNA' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.97
Current: 0.17

0.07
0.97
F-Score: 1
Z-Score: -3.69
M-Score: -3.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -284.75
ARNA's Operating margin (%) is ranked higher than
64% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. ARNA: -284.75 )
ARNA' s 10-Year Operating margin (%) Range
Min: -2405.23   Max: -28.18
Current: -284.75

-2405.23
-28.18
Net-margin (%) -163.67
ARNA's Net-margin (%) is ranked higher than
68% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ARNA: -163.67 )
ARNA' s 10-Year Net-margin (%) Range
Min: -2421.99   Max: -23.88
Current: -163.67

-2421.99
-23.88
ROE (%) -68.08
ARNA's ROE (%) is ranked higher than
61% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. ARNA: -68.08 )
ARNA' s 10-Year ROE (%) Range
Min: -7209.86   Max: -3.29
Current: -68.08

-7209.86
-3.29
ROA (%) -18.73
ARNA's ROA (%) is ranked higher than
76% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. ARNA: -18.73 )
ARNA' s 10-Year ROA (%) Range
Min: -201.16   Max: -3.2
Current: -18.73

-201.16
-3.2
ROC (Joel Greenblatt) (%) -134.36
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. ARNA: -134.36 )
ARNA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -759.39   Max: -30.02
Current: -134.36

-759.39
-30.02
Revenue Growth (3Y)(%) 23.60
ARNA's Revenue Growth (3Y)(%) is ranked higher than
89% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ARNA: 23.60 )
ARNA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 35.1
Current: 23.6

0
35.1
EBITDA Growth (3Y)(%) -29.50
ARNA's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARNA: -29.50 )
ARNA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -70.1   Max: 74.6
Current: -29.5

-70.1
74.6
EPS Growth (3Y)(%) -29.50
ARNA's EPS Growth (3Y)(%) is ranked higher than
62% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ARNA: -29.50 )
ARNA' s 10-Year EPS Growth (3Y)(%) Range
Min: -57.1   Max: 104.7
Current: -29.5

-57.1
104.7
» ARNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ARNA Guru Trades in Q2 2014

Jim Simons 57,355 sh (New)
Murray Stahl 45,000 sh (unchged)
Ken Fisher 11,000 sh (unchged)
» More
Q3 2014

ARNA Guru Trades in Q3 2014

Jim Simons 773,155 sh (+1248.02%)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
Q4 2014

ARNA Guru Trades in Q4 2014

Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
Jim Simons 230,500 sh (-70.19%)
» More
Q1 2015

ARNA Guru Trades in Q1 2015

Ken Fisher 11,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.30
ARNA's P/B is ranked lower than
58% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. ARNA: 19.30 )
ARNA' s 10-Year P/B Range
Min: 0.63   Max: 29.43
Current: 19.3

0.63
29.43
P/S 24.90
ARNA's P/S is ranked higher than
58% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. ARNA: 24.90 )
ARNA' s 10-Year P/S Range
Min: 7.58   Max: 106
Current: 24.9

7.58
106
EV-to-EBIT -9.03
ARNA's EV-to-EBIT is ranked higher than
86% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARNA: -9.03 )
ARNA' s 10-Year EV-to-EBIT Range
Min: -90.1   Max: 0.4
Current: -9.03

-90.1
0.4
Current Ratio 2.70
ARNA's Current Ratio is ranked higher than
64% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ARNA: 2.70 )
ARNA' s 10-Year Current Ratio Range
Min: 2.48   Max: 91.72
Current: 2.7

2.48
91.72
Quick Ratio 2.54
ARNA's Quick Ratio is ranked higher than
65% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. ARNA: 2.54 )
ARNA' s 10-Year Quick Ratio Range
Min: 2.48   Max: 91.72
Current: 2.54

2.48
91.72
Days Inventory 564.43
ARNA's Days Inventory is ranked higher than
77% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARNA: 564.43 )
ARNA' s 10-Year Days Inventory Range
Min: 301.17   Max: 555.68
Current: 564.43

301.17
555.68
Days Sales Outstanding 36.65
ARNA's Days Sales Outstanding is ranked higher than
91% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. ARNA: 36.65 )
ARNA' s 10-Year Days Sales Outstanding Range
Min: 0.8   Max: 602.47
Current: 36.65

0.8
602.47

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.40
ARNA's Price/Tangible Book is ranked lower than
57% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. ARNA: 23.40 )
ARNA' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 25.66
Current: 23.4

0.62
25.66
Price/Median PS Value 1.10
ARNA's Price/Median PS Value is ranked higher than
83% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ARNA: 1.10 )
ARNA' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 2.63
Current: 1.1

0.41
2.63
Earnings Yield (Greenblatt) -11.30
ARNA's Earnings Yield (Greenblatt) is ranked lower than
66% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ARNA: -11.30 )
ARNA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.3   Max: 30966.3
Current: -11.3

-11.3
30966.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RN3.Germany,
Arena Pharmaceuticals Inc was incorporated in the state of Delaware in April 14, 1997, and commenced operations in July 1997. The Company is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ, its internally discovered drug for chronic weight management in adults who are overweight with a comorbidity or obese, is its first and only drug approved for marketing by any regulatory agency. In June 2012, the U.S. Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company is engaged in commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. Its programs include: BELVIQ, for chronic weight management; APD811, an orally available agonist of the prostacyclin (IP) receptor, is an internally discovered investigational drug candidate intended for the treatment of Pulmonary Arterial Hypertension; Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases; APD334, an orally available agonist of the S1P1 receptor, is an internally discovered investigational drug candidate intended for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis; APD371, an orally available agonist of the cannabinoid 2 receptor, is an internally discovered investigational drug candidate intended for the treatment of pain; GPR119, represents pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, granted Eisai Inc., and Eisai Inc.'s parent company, Eisai Co. Ltd. exclusive rights to commercialize BELVIQ in the United States. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's research and development programs involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, the Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.
» More Articles for ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
comment on ARNA Mar 15 2013 
comment on ARNA Mar 02 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
The Westaim Corporation Announces $200 Million “Bought Deal” Private Placement and Concurrent... May 05 2015
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 30 2015
Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of... Apr 29 2015
Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of... Apr 29 2015
5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog Apr 28 2015
Arena Adds Most New Customers in Company History to Close Record Quarter Apr 28 2015
Arena Solutions and Q Point Technology Partner to Offer Arena PLM with Q Point's Online Green Data... Apr 27 2015
Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog Apr 23 2015
Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of... Apr 23 2015
Zacks Rank #5 Additions for Tuesday - Tale of the Tape Apr 21 2015
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 10 2015
Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of... Apr 10 2015
Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen Apr 10 2015
Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference Apr 09 2015
Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference Apr 09 2015
Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog Apr 08 2015
Calls look to ride Arena Pharma Apr 08 2015
Arena Pharmaceuticals (ARNA) Stock Gains Today on New Patent Approval Apr 07 2015
Arena Pharmaceuticals shares rise on weight loss drug patent Apr 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK